Compare VIRC & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIRC | BNR |
|---|---|---|
| Founded | 1950 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 99.1M | 94.4M |
| IPO Year | 1995 | 2019 |
| Metric | VIRC | BNR |
|---|---|---|
| Price | $6.07 | $9.93 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $7.30 | N/A |
| AVG Volume (30 Days) | ★ 28.1K | 4.8K |
| Earning Date | 04-08-2026 | 06-05-2026 |
| Dividend Yield | ★ 1.65% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $199,652,000.00 | N/A |
| Revenue This Year | N/A | $111.65 |
| Revenue Next Year | $19.77 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.16 | $6.79 |
| 52 Week High | $9.07 | $41.72 |
| Indicator | VIRC | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 47.63 | 57.82 |
| Support Level | $6.01 | $8.69 |
| Resistance Level | $6.27 | $12.89 |
| Average True Range (ATR) | 0.14 | 0.41 |
| MACD | -0.01 | 0.18 |
| Stochastic Oscillator | 52.38 | 66.98 |
Virco Manufacturing Corp is engaged in designing, production and distributing quality furniture for the commercial and education markets. The company manufactures an assortment of products, including mobile tables, mobile storage equipment, desks, computer furniture, chairs, activity tables, folding chairs, and folding tables. Its primary furniture lines are constructed of tubular metal legs and frames, combined with wood and plastic tops, plastic seats and backs, upholstered seats and backs, and upholstered rigid polyethylene and polypropylene shells.
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.